Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation.
<h4>Background</h4>Hypercholesterolaemia is common in patients after cardiac transplantation. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol levels and subsequently the risk of cardiovascular event...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0210373 |
id |
doaj-2c56e17c5c2f4607b7412f9977ebdf66 |
---|---|
record_format |
Article |
spelling |
doaj-2c56e17c5c2f4607b7412f9977ebdf662021-03-04T10:37:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01141e021037310.1371/journal.pone.0210373Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation.Michael KühlChristian BinnerJoanna JozwiakJulia FischerJochen HahnAlaeldin AddasBoris DinovJens GarbadeGerhard HindricksMichael Borger<h4>Background</h4>Hypercholesterolaemia is common in patients after cardiac transplantation. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol levels and subsequently the risk of cardiovascular events in patients with dyslipidaemia. There are no published data on the effect of this medication class on cholesterol levels in patients after cardiac transplantation.<h4>Methods</h4>In this retrospective study we investigated patients who were treated with PCSK9 inhibitors either because of intolerance of statins or residual hypercholesterolaemia with evidence of cardiac allograft vasculopathy. We compared the data of patients prior to the start with these medications with their most recent dataset.<h4>Results</h4>Ten patients (nine men; mean age 58±6 years) underwent cardiac transplantation 8.3±4.5 (range 3-15) years ago. The treatment duration of Evolocumab or Alirocumab was on average 296±125 days and lead to a reduction of total Cholesterol (281±52 mg/dl to 197±36 mg/dl; p = 0.002) and LDL Cholesterol (170±22 mg/dl to 101±39 mg/dl; p = 0.001). No significant effects on HDL Cholesterol, BNP, Creatin Kinase or hepatic enzymes were noticed. There were no unplanned hospitalisations, episodes of rejections, change of ejection fraction or opportunistic infections. Both patients on Alirocumab developed liver pathologies: One patient died of hepatocellular carcinoma and the other developed hepatitis E.<h4>Conclusions</h4>Our study demonstrates that the PCSK9 inhibitors Evolocumab and Alirocumab lead to a significant reduction of LDL Cholesterol in heart transplantation recipients. No effect on cardiac function or episodes of rejections were noticed. Larger and long-term studies are needed to establish safety and efficacy of PCSK9 inhibitors after cardiac transplantation.https://doi.org/10.1371/journal.pone.0210373 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michael Kühl Christian Binner Joanna Jozwiak Julia Fischer Jochen Hahn Alaeldin Addas Boris Dinov Jens Garbade Gerhard Hindricks Michael Borger |
spellingShingle |
Michael Kühl Christian Binner Joanna Jozwiak Julia Fischer Jochen Hahn Alaeldin Addas Boris Dinov Jens Garbade Gerhard Hindricks Michael Borger Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation. PLoS ONE |
author_facet |
Michael Kühl Christian Binner Joanna Jozwiak Julia Fischer Jochen Hahn Alaeldin Addas Boris Dinov Jens Garbade Gerhard Hindricks Michael Borger |
author_sort |
Michael Kühl |
title |
Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation. |
title_short |
Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation. |
title_full |
Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation. |
title_fullStr |
Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation. |
title_full_unstemmed |
Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation. |
title_sort |
treatment of hypercholesterolaemia with pcsk9 inhibitors in patients after cardiac transplantation. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
<h4>Background</h4>Hypercholesterolaemia is common in patients after cardiac transplantation. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol levels and subsequently the risk of cardiovascular events in patients with dyslipidaemia. There are no published data on the effect of this medication class on cholesterol levels in patients after cardiac transplantation.<h4>Methods</h4>In this retrospective study we investigated patients who were treated with PCSK9 inhibitors either because of intolerance of statins or residual hypercholesterolaemia with evidence of cardiac allograft vasculopathy. We compared the data of patients prior to the start with these medications with their most recent dataset.<h4>Results</h4>Ten patients (nine men; mean age 58±6 years) underwent cardiac transplantation 8.3±4.5 (range 3-15) years ago. The treatment duration of Evolocumab or Alirocumab was on average 296±125 days and lead to a reduction of total Cholesterol (281±52 mg/dl to 197±36 mg/dl; p = 0.002) and LDL Cholesterol (170±22 mg/dl to 101±39 mg/dl; p = 0.001). No significant effects on HDL Cholesterol, BNP, Creatin Kinase or hepatic enzymes were noticed. There were no unplanned hospitalisations, episodes of rejections, change of ejection fraction or opportunistic infections. Both patients on Alirocumab developed liver pathologies: One patient died of hepatocellular carcinoma and the other developed hepatitis E.<h4>Conclusions</h4>Our study demonstrates that the PCSK9 inhibitors Evolocumab and Alirocumab lead to a significant reduction of LDL Cholesterol in heart transplantation recipients. No effect on cardiac function or episodes of rejections were noticed. Larger and long-term studies are needed to establish safety and efficacy of PCSK9 inhibitors after cardiac transplantation. |
url |
https://doi.org/10.1371/journal.pone.0210373 |
work_keys_str_mv |
AT michaelkuhl treatmentofhypercholesterolaemiawithpcsk9inhibitorsinpatientsaftercardiactransplantation AT christianbinner treatmentofhypercholesterolaemiawithpcsk9inhibitorsinpatientsaftercardiactransplantation AT joannajozwiak treatmentofhypercholesterolaemiawithpcsk9inhibitorsinpatientsaftercardiactransplantation AT juliafischer treatmentofhypercholesterolaemiawithpcsk9inhibitorsinpatientsaftercardiactransplantation AT jochenhahn treatmentofhypercholesterolaemiawithpcsk9inhibitorsinpatientsaftercardiactransplantation AT alaeldinaddas treatmentofhypercholesterolaemiawithpcsk9inhibitorsinpatientsaftercardiactransplantation AT borisdinov treatmentofhypercholesterolaemiawithpcsk9inhibitorsinpatientsaftercardiactransplantation AT jensgarbade treatmentofhypercholesterolaemiawithpcsk9inhibitorsinpatientsaftercardiactransplantation AT gerhardhindricks treatmentofhypercholesterolaemiawithpcsk9inhibitorsinpatientsaftercardiactransplantation AT michaelborger treatmentofhypercholesterolaemiawithpcsk9inhibitorsinpatientsaftercardiactransplantation |
_version_ |
1714805206275850240 |